Pharma Manufacturing

Menu

Newsletters
Subscribe

Newsletters
Subscribe

Follow us on:

Production
Development
Information Technology
Compliance
Quality & Risk
Facilities
Sector

Home|
Solution Providers|
E-News|
Subscribe|
Resource Directory|
Webinars|
Issue archive

Follow us on:

Home / Industry News / 2019 / Pharma in review: trending stories 11/1/19

Pharma in review: trending stories 11/1/19

Nov 01, 2019

Sanofi employees in Bangladesh plan hunger strike protest

number2 Safety concerns halt Novartis gene therapy study

15 manufacturers settle decade old drug pricing case

number4

Mirum grabs breakthrough designation for liver drug

number5

Allergen settles Alzheimer’s suit for $750M

Show More Content

More News:

Execs face jail time for Samsung Biologics fraud

12/09/2019

A court in South Korea has handed out prison sentences for three Samsung executives involved in accounting fraud at the company’s biotech arm.
Merck makes big cancer buy with $2.7B ArQule deal

12/09/2019

Another day — another big oncology deal in pharma.
FDA removes hold on pivotal gene therapy trial

12/09/2019

Abeona Therapeutics announced that the U.S. FDA has removed its clinical hold on the company’s pivotal Phase 3 clinical trial evaluating gene therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
Sanofi to acquire Synthorx for $2.5B

12/09/2019

Sanofi will acquire clinical-stage biotechnology company, Synthorx, for approximately $2.5 billion.
Pharma in review: trending stories 12/6/19

12/06/2019

Most popular Pharma Manufacturing stories from the past seven days.
FDA approves first generics of Novartis blockbuster MS drug

12/06/2019

The U.S. FDA has approved three applications for first generics of Gilenya capsules for the treatment of relapsing forms of multiple sclerosis in adults.
Novartis partners with Amazon to boost manufacturing efficiency

12/06/2019

Novartis will work with Amazon’s cloud-computing unit, Amazon Web Services, to make the manufacturing and delivery of new medicines more efficient.
EMA asks pharma to test diabetes drugs for NDMA

12/04/2019

Common diabetes drugs have become the newest target of an ongoing NDMA scare in pharma.
Merck spars with insurers over $1.3B cyberattack

12/04/2019

Merck says that the attack wiped out years of research data, hampered work at facilities and cost the company $1.3 billion in damages.
Biocon and Mylan nab FDA approval for Herceptin biosim

12/03/2019

Co-developed by both companies, Ogivri will be used for the treatment of breast and gastric cancer patients.

All news

Most Popular

Past 7 Days
Past 30 Days
Past 6 Months

01

Samoan government shuts down over measles outbreak

The Samoan government will shut down for two days as part of a series of…
02

EMA asks pharma to test diabetes drugs for NDMA

Common diabetes drugs have become the newest target of an ongoing NDMA…
03

Lilly opens shared innovation lab

Eli Lilly and Company unveiled its first shared innovation lab, located in…
04

Merck spars with insurers over $1.3B cyberattack

Merck says that the attack wiped out years of research data, hampered work…
05

The future of cold chain logistics

Coming to a supply chain near you

01

Outbreak of a deadly swine fever could trigger global heparin shortage

Heparin, one of the world’s most critical heart medications, could soon…
02

Lonza CEO makes sudden, surprise departure

Lonza investors were reportedly taken aback this week by the surprise…
03

The elephant in the biopharma classroom

Biopharma needs to address its workforce training methods
04

FDA warns Torrent for water system laced with bacteria

The FDA has slapped India-based Torrent Pharmaceuticals with a warning…
05

Samoan government shuts down over measles outbreak

The Samoan government will shut down for two days as part of a series of…

01

2019 Pharma Innovation Awards

This year's winners offer slices of innovation
02

Pharma's budding opportunity

Why the industry is forming bonds with CBD
03

What’s behind all the M&A deals in pharma?

As far as M&A deals go, 2019 has started off with a boom.
04

Making the case for Indian generic drug manufacturing

In response to the growing regulatory environment, pharmaceutical…
05

CDMO trends: Drug development and industry consolidation

How those in the outsourcing sector can be more prepared to meet shifting…

Pharma Manufacturing

About

General Information
Contact Us
Subscription Services
Media Kit
Editorial Calendar
Editorial Submissions Guidelines
Editorial Advisory Board

Content

Resource Libraries
OpEd
Fundamentals
News
Articles
White Papers
Products
All Star Innovators
Funny Pharm

Magazine

Subscribe (print)
Current Issue
Issue Archive

Site Tools

Site Map
Resource Directory

Stay Connected

My Account
Events Calendar
E-Newsletters
Human Interest
Facebook
Twitter
LinkedIn
YouTube
RSS Feed

Contact Us | Advertise | Privacy Policy | Legal Disclaimers, Terms & Conditions

Copyright © 2004 - 2019 Pharma Manufacturing. All rights reserved.

P: 630-467-1300 | 1501 E. Woodfield Road, Suite 400N, Schaumburg, IL 60173

Chemical Processing | Control | Control Design | Food Processing | Pharma Manufacturing | Plant Services | Smart Industry